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Approximately 13% of all breast cancer patients
have one or more ﬁrst-degree relatives with breast
cancer [1]. The overall Relative Risk for a ﬁrst-degree
relative to develop breast cancer herself (also termed
excess familial risk) is approximately 1.80. How much
of this risk is determined by genetic factors? A large
Scandinavian twin study has indicated that 27% of the
variance in susceptibility was attributable to heritable
factors. Peto and Mack [2] observed that patients with
breast cancer are at a very high risk of developing
another cancer in the other breast and that this risk
does not change with the age of the ﬁrst cancer, being
approximately 0.7% per year. They argue that most of
this high-risk is genetic because a similar pattern is
seen in monozygotic twins, where the risk is ap-
proximately twice the contralateral breast cancer risk
of any individual, which is consistent given that in the
latter case only one breast is at risk. The inference of
their model is that the ﬁrst cancer (i.e., breast cancers
in the population as a whole) occurs in a minority of
women who are susceptible for it. A more conven-
tional model of inherited breast cancer susceptibility is
that disease risks are aﬀected by mutations in a small
number of genes causing a high-risk of the disease,
and a larger number of lower risk gene variants
probably interacting together [3]. Model-based linkage
analysis in multiple-case families followed by posi-
tional cloning led to the identiﬁcation of several high-
risk breast cancer susceptibility genes. BRCA1 and
BRCA2 are the most well known of these, and the
cancer risks conferred by mutations in these genes are
now well established. It has been estimated that mu-
tations in BRCA1 and BRCA2 can explain only ap-
proximately 25% of the overall excess familial risk.
Families with at least four cases of breast cancer and
at least one case of ovarian cancer can be attributed
largely to BRCA1. Multiple-case families with at least
one case of male breast cancer are mainly due to
BRCA2. However, most families with four or ﬁve
cases of female breast cancer diagnosed before the age
of 60 years are not due to BRCA1 or BRCA2 [4]. This
has been taken as evidence that one or more moder-
ate- to high-risk breast cancer susceptibility genes still
remain to be identiﬁed. There have indeed been sev-
eral linkage claims since BRCA1 and BRCA2 were
identiﬁed, but none of these have been replicated in
other, often larger studies. However, most studies are
heavily underpowered to detect a new breast cancer
locus by linkage in the presence of substantial genetic
heterogeneity. If BRCA3 causes familial breast cancer
in only 25% of such families, over 300 families would
be required to detect it by conventional linkage ana-
lysis. The Breast Cancer Linkage Consortium is cur-
rently compiling genome-wide linkage data on
approximately 200 families in which the role of
BRCA1 or BRCA2 has been excluded with >90%
certainty. This comprises the largest linkage search
eﬀort in the world to date. These families are char-
acterised by the presence of at least three cases of
breast cancer diagnosed before the age of 60 years, no
cases of ovarian or male breast cancer.
A model in which several common, low penetrance
genes with multiplicative eﬀects on risk could also
account for the residual non-BRCA1/BRCA2 familial
aggregation [5]. The biggest immediate challenge now
is to identify such genetic factors. Parametric linkage
analysis in families is not feasible, and here one gen-
erally relies on some form of genetic association study.
As genome-wide searches for associations between
genetic variation and disease susceptibility are pre-
sently still too costly, the study design most often
opted for is one in which a functional variant in a
candidate gene is selected, and its prevalence assayed
* Tel.: +31 71 5276293; fax: +31 71 5276075.
E-mail address: p.devilee@lumc.nl.
1359-6349/$ - see front matter  2004 Elsevier Ltd. All rights reserved.
doi:10.1016/j.ejcsup.2004.08.007
EJC Supplements Vol 2 No. 9 (2004) 29–30
www.ejconline.com
EJC
Supplements
in a population of cases and controls. The present
state of this research area is characterised by many
conﬂicting results. Whereas everybody agrees that
genes involved in oestrogen biosynthesis and metabo-
lism, DNA repair, apoptosis, and cell cycle control are
all good candidates for breast cancer risk factors, it is
very often not clear what the functional relevance of
genetic variation in these genes is. In addition, hidden
population stratiﬁcation may give rise to false-positive
or false-negative results, and many association studies
have in fact been conducted on too small populations.
Finally, there is a debate raging in the literature be-
tween proponents of a model which assumes that
most disease susceptibility variants are common in the
population (frequency > 1%) versus those that assume
that late-onset diseases are due to large numbers of
rare variants at many loci [6,7]. Under the ﬁrst model,
common susceptibility alleles are potentially detectable
in large-scale patient-control association studies, but
under the last model, such a strategy would fail and
the contribution of most individual variants would be
too small to further our understanding of disease.
If all of the susceptibility factors could be identiﬁed, it
would, in principle, be possible to identify women as
susceptible for breast cancer by their genotypic proﬁle,
opening up avenues for targeted breast cancer prevention
[8]. However, population-based gene testing for breast
cancer will never become acceptable in the absence of a
cost-eﬀective, non-invasive preventive intervention.
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